Back to clinical trials
RecruitingObservational
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
NCT ID: NCT04085029Sponsor: Duke UniversityLast updated: 2026-02-05
Summary
The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.
Outcome measures
Primary
Occurrence of acute adverse events following radiotherapy
Time frame: 90 Days
Eligibility criteria
Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria:
* Age ≥ 18 years of age
* Radiographic evidence of metastatic disease (may include oligoprogression, oligorecurrence or oligometastasis) at the time of study enrollment
* Planned to receive, currently receiving, or have completed hypofractionated image guided radiotherapy (ablative radiotherapy) to an extracranial site(s)
* Patient must sign study-specific informed consent
Exclusion Criteria:
• None
Study locations (5)
Duke Cancer Institute Cary
Cary, North Carolina, 27518
Durham Veterans Administration Health Care System (DVAHCS)
Durham, North Carolina, 27705
Joseph Salama, MD · Principal Investigator
Duke University Medical Center
Durham, North Carolina, 27710
Duke Women's Cancer Care Raleigh
Raleigh, North Carolina, 27607
Duke Raleigh Hospital
Raleigh, North Carolina, 27609